journal article·2024-09-20Open access

Glioma Stem Cells: GPRC5A as a Novel Predictive Biomarker and Therapeutic Target Associated with Mesenchymal and Stemness Features

Sara Sadat Aghamiri, Rada Amin

Applied Sciences· Volume 14· Issue 18

Abstract

Glioblastoma multiforme (GBM) represents the deadliest form of brain cancer, characterized by complex interactions within its microenvironment. Despite the understanding of GBM biology, GBM remains highly resistant to any therapy. Therefore, defining innovative biomarkers in GBM can provide insights into tumor biology and potential therapeutic targets. In this study, we explored the potential of GPRC5A to serve as a pertinent biomarker for GBM. We utilized the GBM-TCGA dataset and presented the reproducible bioinformatics analysis for our results. We identified that GPRC5A expression was significantly upregulated in GBM compared to normal tissues, with higher levels correlating with poor overall survival (OS) and progression-free interval (PFI). Moreover, it was associated with key genetic mutations, particularly NF1 and PTEN mutations, and strongly correlated with the mesenchymal stem-like phenotype. GPRC5A was also predominantly associated with aggressive GBM features, including hypoxia, high extracellular matrix (ECM) environments, and extensive stromal and immune infiltrations. Its strong correlation with mesenchymal markers and hypoxic regions underscores its potential as a biomarker and therapeutic target in GBM. These findings provide valuable insights into the role of GPRC5A in GBM pathology and its potential impact as a target for GBM stratifications and treatment strategies.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Glioma Diagnosis and Treatment · Cancer Cells and Metastasis · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biochemistry, University of Nebraska, Lincoln, NE 68503, USA

References (87)

Show source-provided references
1. Tumor microenvironment in glioblastoma: Current and emerging concepts10.1093/noajnl/vdad009 ↗
2. Shi, T., Zhu, J., Zhang, X., and Mao, X. (2023). The role of hypoxia and cancer stem cells in development of glioblastoma. Cancers, 15.10.3390/cancers15092613 ↗
3. Molecular alterations in glioblastoma: Potential targets for immunotherapy10.1016/B978-0-12-385506-0.00005-3 ↗
4. Liu, A., Hou, C., Chen, H., Zong, X., and Zong, P. (2016). Genetics and epigenetics of glioblastoma: Applications and overall incidence of IDH1 mutation. Front. Oncol., 6.10.3389/fonc.2016.00016 ↗
5. Chiariello, M., Inzalaco, G., Barone, V., and Gherardini, L. (2023). Overcoming challenges in glioblastoma treatment: Targeting infiltrating cancer cells and harnessing the tumor microenvironment. Front. Cell. Neurosci., 17.10.3389/fncel.2023.1327621 ↗
6. Liguori, G.L. (2024). Challenges and Promise for Glioblastoma Treatment through Extracellular Vesicle Inquiry. Cells, 13.10.3390/cells13040336 ↗
7. Cancer stem cell metastatic checkpoints and glycosylation patterns: Implications for therapeutic strategies10.3390/kinasesphosphatases2020009 ↗
8. Tripathy, D.K., Panda, L.P., Biswal, S., and Barhwal, K. (2024). Insights into the glioblastoma tumor microenvironment: Current and emerging therapeutic approaches. Front. Pharmacol., 15.10.3389/fphar.2024.1355242 ↗
9. The role of tregs in glioma-mediated immunosuppression: Potential target for intervention10.1016/j.nec.2009.08.012 ↗
10. Alban, T.J., Bayik, D., Otvos, B., Rabljenovic, A., Leng, L., Jia-Shiun, L., Roversi, G., Lauko, A., Momin, A.A., and Mohammadi, A.M. (2020). Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression. Front. Immunol., 11.10.3389/fimmu.2020.01191 ↗
11. Macrophages and microglia in glioblastoma: Heterogeneity, plasticity, and therapy10.1172/JCI163446 ↗
12. Glioblastoma microenvironment: The stromal interactions10.1016/j.prp.2022.153813 ↗
13. Extracellular matrix in glioblastoma: Opportunities for emerging therapeutic approaches
14. Hypoxia and the extracellular matrix: Drivers of tumour metastasis10.1038/nrc3726 ↗
15. Clinical implications of intratumor heterogeneity: Challenges and opportunities10.1007/s00109-020-01874-2 ↗
16. Sareen, H., Ma, Y., Becker, T.M., Roberts, T.L., de Souza, P., and Powter, B. (2022). Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 23.10.3390/ijms23168835 ↗
17. Glioblastoma stem cells: Lessons from the tumor hierarchy in a lethal cancer10.1101/gad.324301.119 ↗
18. Role of glioblastoma stem cells in cancer therapeutic resistance: A perspective on antineoplastic agents from natural sources and chemical derivatives10.1186/s13287-021-02231-x ↗
19. Glioblastoma Stem Cells: Driving Resilience through Chaos10.1016/j.trecan.2020.01.009 ↗
20. Cancer stem cell surface markers on normal stem cells10.5483/BMBRep.2017.50.6.039 ↗
21. Hassn Mesrati, M., Behrooz, A.B., Y. Abuhamad, A., and Syahir, A. (2020). Understanding Glioblastoma Biomarkers: Knocking a Mountain with a Hammer. Cells, 9.10.3390/cells9051236 ↗
22. Standard clinical approaches and emerging modalities for glioblastoma imaging10.1093/noajnl/vdac080 ↗
23. Jiang, X., Xu, X., Wu, M., Guan, Z., Su, X., Chen, S., Wang, H., and Teng, L. (2018). GPRC5A: An emerging biomarker in human cancer. BioMed Res. Int., 2018.10.1155/2018/1823726 ↗
24. Orphan G protein-coupled receptor GPRC5A modulates integrin β1-mediated epithelial cell adhesion10.1080/19336918.2016.1245264 ↗
25. Jahny, E., Yang, H., Liu, B., Jahnke, B., Lademann, F., Knösel, T., Rümmele, P., Grützmann, R., Aust, D.E., and Pilarsky, C. (2017). The G Protein-Coupled Receptor RAI3 Is an Independent Prognostic Factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation. PLoS ONE, 12.10.1371/journal.pone.0170390 ↗
26. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene10.1093/jnci/djm208 ↗
27. Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis10.1158/1940-6207.CAPR-10-0032 ↗
28. GPRC5A is a potential prognostic biomarker and correlates with immune cell infiltration in non-small cell lung cancer10.21037/tlcr-23-739 ↗
29. Differential Expression of Hypoxia-Related Genes in Primary Brain Tumors and Correlation with Clinicopathologic Data10.1016/j.wneu.2021.07.068 ↗
30. miR-342 inhibits glioma cell proliferation by targeting GPRC5A
31. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses10.1093/nar/gkx247 ↗
32. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF110.1016/j.ccr.2009.12.020 ↗
33. CNS tumor stroma transcriptomics identify perivascular fibroblasts as predictors of immunotherapy resistance in glioblastoma patients10.1038/s41525-023-00381-w ↗
34. Single-cell RNA sequencing and spatial transcriptomics reveal cancer-associated fibroblasts in glioblastoma with protumoral effects10.1172/JCI147087 ↗
35. CellMarker 2.0: An updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data10.1093/nar/gkac947 ↗
36. Visualizing and interpreting cancer genomics data via the Xena platform10.1038/s41587-020-0546-8 ↗
37. Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes10.1016/j.cell.2020.04.055 ↗
38. Xiong, A., Zhang, J., Chen, Y., Zhang, Y., and Yang, F. (2022). Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM. EBioMedicine, 83.10.1016/j.ebiom.2022.104239 ↗
39. Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression10.1038/s41590-022-01215-0 ↗
40. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data10.1158/2159-8290.CD-12-0095 ↗
41. TIMER2.0 for analysis of tumor-infiltrating immune cells10.1093/nar/gkaa407 ↗
42. TISIDB: An integrated repository portal for tumor-immune system interactions10.1093/bioinformatics/btz210 ↗
43. Histology-based expression profiling yields novel prognostic markers in human glioblastoma10.1097/01.jnen.0000186940.14779.90 ↗
44. An anatomic transcriptional atlas of human glioblastoma10.1126/science.aaf2666 ↗
45. Inferring tumour purity and stromal and immune cell admixture from expression data10.1038/ncomms3612 ↗
46. Cancer Genome Atlas Research Network Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma10.1016/j.ccr.2010.03.017 ↗
47. MGMT status as a clinical biomarker in glioblastoma10.1016/j.trecan.2020.02.010 ↗
48. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy10.1038/s41467-020-17186-5 ↗
49. Inoue, A., Ohnishi, T., Nishikawa, M., Ohtsuka, Y., Kusakabe, K., Yano, H., Tanaka, J., and Kunieda, T. (2023). A narrative review on cd44’s role in glioblastoma invasion, proliferation, and tumor recurrence. Cancers, 15.10.3390/cancers15194898 ↗
50. An overview of CD133 as a functional unit of prognosis and treatment resistance in glioblastoma10.3390/curroncol30090601 ↗
51. Wang, M., Shen, S., Hou, F., and Yan, Y. (2022). Pathophysiological roles of integrins in gliomas from the perspective of glioma stem cells. Front. Cell Dev. Biol., 10.10.3389/fcell.2022.962481 ↗
52. Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles10.1080/20013078.2017.1359479 ↗
53. Gilder, A.S., Natali, L., Van Dyk, D.M., Zalfa, C., Banki, M.A., Pizzo, D.P., Wang, H., Klemke, R.L., Mantuano, E., and Gonias, S.L. (2018). The urokinase receptor induces a mesenchymal gene expression signature in glioblastoma cells and promotes tumor cell survival in neurospheres. Sci. Rep., 8.10.1038/s41598-018-21358-1 ↗
54. CXCR4 and Glioblastoma10.2174/1871520615666150824153032 ↗
55. Differential Nrf2 expression between glioma stem cells and non-stem-like cells in glioblastoma10.3892/ol.2013.1760 ↗
56. PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling10.1038/s41388-022-02294-x ↗
57. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population10.1158/0008-5472.CAN-03-2073 ↗
58. “Pseudopalisading” necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis10.1097/00005072-200606000-00001 ↗
59. Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors10.1080/2162402X.2019.1655360 ↗
60. Dai, L., Jin, X., and Liu, Z. (2021). Prognostic and clinicopathological significance of GPRC5A in various cancers: A systematic review and meta-analysis. PLoS ONE, 16.10.1371/journal.pone.0249040 ↗
61. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR10.1038/cddis.2016.169 ↗
62. Tang, X., Zuo, C., Fang, P., Liu, G., Qiu, Y., Huang, Y., and Tang, R. (2021). Targeting glioblastoma stem cells: A review on biomarkers, signal pathways and targeted therapy. Front. Oncol., 11.10.3389/fonc.2021.701291 ↗
63. circGprc5a Promoted Bladder Oncogenesis and Metastasis through Gprc5a-Targeting Peptide10.1016/j.omtn.2018.10.008 ↗
64. Heparanase promotes myeloma stemness and in vivo tumorigenesis10.1016/j.matbio.2019.11.004 ↗
65. Proneural and mesenchymal glioma stem cells display major differences in splicing and lncRNA profiles10.1038/s41525-019-0108-5 ↗
66. Steponaitis, G., and Tamasauskas, A. (2021). Mesenchymal and proneural subtypes of glioblastoma disclose branching based on GSC associated signature. Int. J. Mol. Sci., 22.10.3390/ijms22094964 ↗
67. Garnier, D., Renoult, O., Alves-Guerra, M.-C., Paris, F., and Pecqueur, C. (2019). Glioblastoma Stem-Like Cells, Metabolic Strategy to Kill a Challenging Target. Front. Oncol., 9.10.3389/fonc.2019.00118 ↗
68. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma10.1016/j.ccr.2013.08.001 ↗
69. CXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma10.1002/ijc.34329 ↗
70. Epithelial-mesenchymal transition in glioblastoma progression10.3892/ol.2016.4113 ↗
71. Fedele, M., Cerchia, L., Pegoraro, S., Sgarra, R., and Manfioletti, G. (2019). Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma. Int. J. Mol. Sci., 20.10.3390/ijms20112746 ↗
72. Tumor-Infiltrating Natural Killer Cells10.1158/2159-8290.CD-20-0655 ↗
73. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas10.1111/imcb.12225 ↗
74. Differential targeting of stem cells and differentiated glioblastomas by NK cells10.7150/jca.11527 ↗
75. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells10.1007/s00262-016-1866-x ↗
76. Mast cells modulate proliferation, migration and stemness of glioma cells through downregulation of GSK3β expression and inhibition of STAT3 activation10.1016/j.cellsig.2017.06.004 ↗
77. Brettschneider, E.E.S., and Terabe, M. (2021). The role of NKT cells in glioblastoma. Cells, 10.10.3390/cells10071641 ↗
78. Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma10.1038/s41467-023-35957-8 ↗
79. Understanding the immunosuppressive microenvironment of glioma: Mechanistic insights and clinical perspectives10.1186/s13045-024-01544-7 ↗
80. Martinez-Morga, M., Garrigos, D., Rodriguez-Montero, E., Pombero, A., Garcia-Lopez, R., and Martinez, S. (2024). Pericytes are immunoregulatory cells in glioma genesis and progression. Int. J. Mol. Sci., 25.10.3390/ijms25105072 ↗
81. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling10.1038/s41422-021-00528-3 ↗
82. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth10.1016/j.cell.2013.02.021 ↗
83. Proliferation of vascular smooth muscle cells in glioblastoma multiforme10.3171/2009.10.JNS08631 ↗
84. CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo10.2174/156720211796558023 ↗
85. The adaptive transition of glioblastoma stem cells and its implications on treatments10.1038/s41392-021-00491-w ↗
86. Mosteiro, A., Pedrosa, L., Ferrés, A., Diao, D., Sierra, À., and González, J.J. (2022). The vascular microenvironment in glioblastoma: A comprehensive review. Biomedicines, 10.10.3390/biomedicines10061285 ↗
87. Isavand, P., Aghamiri, S.S., and Amin, R. (2024). Applications of Multimodal Artificial Intelligence in Non-Hodgkin Lymphoma B Cells. Biomedicines, 12.10.3390/biomedicines12081753 ↗